We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Trophos Awarded Key US Patent Covering Use of Novel Cardioprotective Compound, TRO40303
Product News

Trophos Awarded Key US Patent Covering Use of Novel Cardioprotective Compound, TRO40303

Trophos Awarded Key US Patent Covering Use of Novel Cardioprotective Compound, TRO40303
Product News

Trophos Awarded Key US Patent Covering Use of Novel Cardioprotective Compound, TRO40303


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Trophos Awarded Key US Patent Covering Use of Novel Cardioprotective Compound, TRO40303"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Trophos SA has announced that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection.

The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).

The U.S. Patent, No. 7,985,774, is entitled "Use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug". This covers most notably inter alia cardiovascular indications, including the lead indication in clinical development of reducing cardiac ischemia-reperfusion injury.

The patent also covers the use of TRO40303 and derivatives in treating a wide range of non-neurological degenerative diseases characterized by pathological cell death, and/or cell dysfunctions leading to cell death.

These cell dysfunctions may for example be of mitochondrial origin such as a reduction in the capability of generating ATP, an incapability of capturing and/or retaining calcium, or the generation of free radicals.

“The granting of this key patent in the US by the USPTO is an important milestone for Trophos. TRO40303 will shortly enter a phase II proof-of-concept study to treat cardiac ischemia-reperfusion injury (IRI) in acute MI patients as part of an EU funded international translational medicine project, MitoCare, led by Trophos,” said Damian Marron, CEO at Trophos.

Marron continued, “TRO40303’s potential in degenerative diseases was discovered using Trophos’ pioneering, proprietary screening assays and was characterized and developed by Trophos’ expert R&D teams in collaboration with leading external collaborators.”

A treatment is urgently required globally to prevent cardiac reperfusion injury, which is a major problem in the care of MI patients despite the overall improvements in prognosis in recent years. There is still no existing treatment for the problem that contributes to long-term morbidity, progression to heart failure and death following an MI.

The role of mitochondrial permeability transition in cardiac reperfusion injury has recently been validated clinically. This creates a tremendous opportunity for Trophos’ novel mitochondrial pore modulator, TRO40303, both discovered and developed in the Trophos laboratories to target this mechanism. There are around 1.6 million cardiac reperfusion procedures performed in hospitals and specialist clinics each year in the western world alone.

The phase II proof-of-concept study of TRO40303 is to be sponsored by Trophos and performed as part of the EU funded MitoCare project (see below) by a consortium of prominent European clinical investigators, all of whom have extensive prior experience conducting and collaborating in large multi-centre clinical trials in cardiac IRI.

The principal investigator will be professor Dan Atar from Oslo University Hospital, Norway. The study will be a placebo-controlled, phase II proof-of-concept study in acute MI patients with large myocardial infarct undergoing percutaneous transluminal coronary angioplasty (PTCA also known as coronary or balloon angioplasty) during percutaneous coronary intervention (PCI). TRO40303 will be administered as a single iv infusion prior to the reperfusion by angioplasty.

MitoCare is a two and a half year international, translational medicine project funded by a European Union award of EUR six million. MitoCare, which began in January 2011 (see release of December 14th 2010), is being conducted by a 16 partner consortium and led by Trophos.

MitoCare forms part of the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (FP7).

MitoCare will investigate the efficacy and safety of TRO40303 in a phase II proof-of-concept study to treat cardiac ischemia-reperfusion injury (IRI) in acute myocardial infarction (MI) patients and develop knowledge of biomarkers and models of cardiac ischemia-reperfusion injury.

Advertisement